Share

    


In This Section

Home / Learn / Skin Cancer

Skin Cancer

Skin cancer is the most common cancer in the United States.1,2 The incidence of skin cancer (basal cell, squamous cell, and melanoma) has been on the rise for a number of years. This increase is likely due to a combination of factors: more awareness and screening, better detection, increased longevity, and more sun exposure.3 

Estimates are that nonmelanoma skin cancers, which include basal cell and squamous cell carcinomas, affect over 3 million Americans a year.4 Of the two, basal cell carcinoma is more common. Both of these types of skin cancer rarely spread to other parts of the body and are curable when detected early and treated appropriately. 

Melanoma, although far less common, is much more likely to spread to other parts of the body. While only 1 percent of skin cancers are melanomas, this type of skin cancer is responsible for the majority of skin cancer deaths.1

Sources:
1 American Cancer Society. Key Statistics for Skin Cancer.
2 Guy GP, Thomas CC, Thompson T, Watson M, Massetti GM, Richardson LC. Vital signs: Melanoma incidence and mortality trends and projections—United States, 1982–2030. MMWR Morb Mortal Wkly Rep. 2015;64(21):591-596.
3 American Cancer Society. Key Statistics for Basal Cell and Squamous Cell Carcinomas.
4 American Cancer Society. Key Statistics for Melanoma.



From Oncology Issues

  •  9 Steps to Hosting Your Own Skin Cancer Screening
  •  Developing Skin Cancer Prevention Initiatives for the Whole Family
    By Debra DeNitto, BS
    In 2016, Valley Health, a not-for-profit healthcare system serving patients in Maryland, Virginia, and West Virginia, partnered with a local dermatology office and various community and state stakeholders on a common goal to educate our community about smart sun protection decisions and the importance of skin cancer screenings.
  •  Skin Cancer Screening Business Model
    Skin Cancer Screening Business Model
  •  Patient-Specific Therapeutic Vaccines for Metastatic Melanoma
    Robert O. Dillman, MD
    The only standard treatments for metastatic melanoma that have been associated with long-term overall survival (OS) are surgical resection, and immunotherapies that include the immune-stimulating cytokine interleukin-2 (IL2), the anticytotoxic T lymphocyte antigen-4 (CTLA-4) monoclonal antibody ipilimumab, and the anti-programmed death 1 (PD1) monoclonal antibodies nivolumab and pembrolizumab (aka lambrolizumab).
  •  Stop Cancer Before It Starts!
    Melanie Gonzales, MSPH, MCHES, and Vicky Jekich, CMP
    While young people across the U.S. are able to access more information through technology with greater speed, they may be misinformed or lack understanding of how unhealthy behaviors can put their health at risk.
  •  Best of ASCO 2017
    Cary A. Presant, MD, FACP, FASCO
    ASCO 2017 was filled with new information and long lines as 39,000 oncologists worldwide came together to hear the latest advances in cancer care.
  •  Fox Chase Cancer Center Care Connect
    Kelly Filchner, MSN, RN, OCN, CCRC, and Alan Howald, BS
    Fox Chase Cancer Center, Philadelphia, Pa., committed resources to develop a program to improve communication and education between oncology and primary care, and improve overall survivorship care.

ACCCBuzz Blog Posts